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AbstrACt
Objectives To summarise and synthesise the current 
evidence regarding the effectiveness of drug interventions 
to prevent sudden cardiac death (SCD) and all-cause 
mortality in patients with heart failure with reduced 
ejection fraction (HFrEF).
Design Overview of systematic reviews.
Data sources MEDLINE, Embase, ISI Web of Science and 
Cochrane Library from inception to May 2017; manual 
search of references of included studies for potentially 
relevant reviews.
Eligibility criteria for study selection We reviewed the 
effectiveness of drug interventions for SCD and all-cause 
mortality prevention in patients with HFrEF. We included 
overviews, systematic reviews and meta-analyses of 
randomised controlled trials of beta-blockers, angiotensin-
converting enzyme inhibitors (ACE-i), angiotensin receptor 
blockers (ARBs), antialdosterones or mineralocorticoid-
receptor antagonists, amiodarone, other antiarrhythmic 
drugs, combined ARB/neprilysin inhibitors, statins and fish 
oil supplementation.
review methods Two independent reviewers extracted 
data and assessed the methodological quality of the 
reviews and the quality of evidence for the primary 
studies for each drug intervention, using Assessing 
the Methodological Quality of Systematic Reviews 
(AMSTAR) and Grading of Recommendations, Assessment, 
Development and Evaluation(GRADE), respectively.
results We identified 41 reviews. Beta-blockers, 
antialdosterones and combined ARB/neprilysin inhibitors 
appeared effective to prevent SCD and all-cause mortality. 
ACE-i significantly reduced all-cause mortality but not 
SCD events. ARBs and statins were ineffective where 
antiarrhythmic drugs and omega-3 fatty acids had unclear 
evidence of effectiveness for prevention of SCD and all-
cause mortality.
Conclusions This comprehensive overview of systematic 
reviews confirms that beta-blockers, antialdosterone 
agents and combined ARB/neprilysin inhibitors are 
effective on SCD prevention but not ACE-i or ARBs. In 
patients with high risk of SCD, an alternative therapeutic 
strategy should be explored in future research.
systematic review registration PROSPERO 2017: 
CRD42017067442.
IntrODuCtIOn  
Heart failure (HF) morbidity and mortality 
constitute an important burden for patients 
and for the healthcare systems in both devel-
oped and developing countries.1 Patients 
with HF are frequently hospitalised and have 
a high mortality risk because of a poor prog-
nosis or an unexpected death, termed sudden 
cardiac death (SCD). In people diagnosed 
with HF, SCD occurs at 6–9 times the rate of 
the general population. Almost 20% and 80% 
of patients die within one year and eight years 
of initial diagnosis, respectively.1 2 Risk factors 
of SCD were reported to be similar to cardio-
vascular diseases. However, the most studied 
and proven predictor of SCD in patients 
with HF is left ventricular ejection fraction.3 
Potential drug interventions in patients with 
heart failure with reduced ejection fraction 
(HFrEF) include beta-blockers (BBs), angio-
tensin-converting enzyme inhibitors (ACE-
i), angiotensin receptor blockers (ARBs), 
antialdosterones or mineralocorticoid 
receptor antagonists, amiodarone, other 
strengths and limitations of this study
 ► A major strength of our study is that it summaris-
es and synthesises the effectiveness of most evi-
dence-based drug interventions in heart failure 
patients with reduced ejection fraction for sudden 
cardiac death (SCD) prevention and classified drug 
interventions according to the current evidence of 
their effectiveness.
 ► Our study used data from published studies and no 
data from unpublished studies.
 ► Our study reviews most heart failure drugs on the 
prevention of SCD and all-cause mortality but lim-
ited in scope for not including some drugs such as 
digoxin, ivabradine and non-drug interventions/de-
vices such as implantable cardioverter defibrillators.
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antiarrhythmic agents, combined ARB/neprilysin inhib-
itors, statins and fish oil supplementation.4 Some of these 
interventions aimed at improving survival and reducing 
total mortality and SCD in HF. For instance, a newly 
licensed drug (sacubitril/valsartan) in PARADIGM-HF 
trial (Prospective Comparison of angiotensin neprilysin 
inhibitor (ARNI) with ACE-i to Determine Impact on 
Global Morbidity and Mortality in Heart Failure) showed 
around 20% SCD reduction compared with enalapril.5 
Nevertheless, optimal strategies for SCD prevention 
in HF are warranted if we take into account the high 
portion of mortality that still occurs in this population. 
Had a practitioner identified a patient with high risk of 
SCD, it would be important to know which drug is effec-
tive or not in SCD prevention other than non-drug inter-
ventions such as implantable cardioverter defibrillators 
(ICDs). However, the large amount of information and 
the multiple and sometimes discordant systematic reviews 
on drug interventions could be misleading.6
Therefore, it is vital to identify the pharmacological 
agents that confer the greatest benefit in SCD risk reduc-
tion particularly in high-risk patients and if any optimisa-
tion of therapeutic strategies to those patients is possible 
accordingly. Thus, we decided to conduct an overview 
of systematic reviews to summarise and synthesise the 
available evidence about the effectiveness of drug inter-
ventions in the prevention of SCD in HFrEF and catego-
rised the evidence into effective, ineffective and unclear 
evidence of effectiveness.
MEthODs
We developed an a priori protocol for this review 
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses statement (online supple-
mentary file S1) and registered it in the PROSPERO 
International prospective register of systematic reviews 
(CRD42017067442).
Data sources and search strategy
Using the Ovid online interface, we searched MEDLINE 
(up to 24 May 2017), Embase (up to 23 May 2017), ISI 
Web of Science and the Cochrane Library (up to 24 May 
2017). We identified overviews, systematic reviews and 
meta-analyses of randomised clinical trials by means of 
a search strategy (available on online supplementary 
file S2). The search strategy was composed of a filter,7 8 
a mixture of Medical Subject Heading terms (MeSH and 
EMTREE in MEDLINE and Embase, respectively), text 
words as well as a truncation when possible without any 
language or publication date restriction. We did not 
search conference proceedings nor the grey literature. 
Reference lists of the included reviews were manually 
checked for any additional eligible studies. We contacted 
corresponding reviews’ and primary studies’ authors to 
seek for relevant unreported data. If judged necessary, 
we intended to update the included reviews by searching 
primary studies published after the systematic review 
publication date. Apart from authors’ expertise in the 
field, we decided to update if the most up-to-date review 
of a drug intervention was published more than 5 years 
ago and/or new clinical trials are not integrated into the 
evidence.
selection criteria and data abstraction
Studies were eligible if they were overviews, systematic 
reviews and meta-analyses of randomised clinical trials 
that evaluated the effectiveness of drug interventions in 
patients with HFrEF. Reviews were included if they exam-
ined the effectiveness of the following drugs: BBs, ACE-i, 
ARBs, antialdosterones or mineralocorticoid receptor 
antagonists, amiodarone, antiarrhythmics, combined 
ARB/neprilysin inhibitors, statins and fish oil supple-
mentation. The selected reviews should have contained 
at least one of the aforementioned HF therapy and had 
evaluated SCD and/or all-cause mortality prevention as 
outcomes. We used Endnote and Rayyan9 to remove dupli-
cates during the selection based on titles and abstracts, 
and full-text screening.
The abstracted data included eligibility criteria, popula-
tion type, ejection fraction, study design (including inter-
vention and comparator arms), follow-up duration and 
authors’ evaluation of outcomes. Two reviewers (MA and 
SA) independently abstracted data. We resolved discrep-
ancies by consensus or by adding a third reviewer’s judge-
ment when necessary.
Quality assessment of the included reviews
Methodological quality of the included reviews
Two authors (MA and SA) independently used the 
AMSTAR (Assessing the Methodological Quality of 
Systematic Reviews) measurement tool to assess systematic 
reviews included in our overview. The AMSTAR checklist 
comprises 11 questions (online supplementary S3 table) 
and each question accounted for one score point.10 The 
answer of ‘yes’ gave a score of 1 and zero otherwise. This 
increasingly adopted tool was used at the data collection 
step as stipulated in the overview protocol.11 If the authors 
of included reviews failed to publish their protocol, we 
deducted a score of one. In addition, we scored ‘yes’ if 
the authors mentioned that two reviewers were involved 
in the study screening, selection or data extraction.
Quality of evidence in the included reviews
Two authors (MA and SA) independently used the 
Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) approach12 to assess the 
quality of evidence of each intervention. GRADE is a 
widely accepted tool that allows the assessment of five key 
elements: risk of bias, inconsistency, indirectness, impreci-
sion and publication bias. GRADE categorises the quality 
of evidence into four levels: high, moderate, low and very 
low. In the presence of a high risk of bias, the quality of 
the evidence is downgraded from high to moderate and 
so on. We also reported the GRADE assessments reported 
by the authors of the included reviews, or assessed them 
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otherwise. Moreover, we did not reassess the risk of bias 
at primary study level if authors of included reviews 
had sufficiently assessed their quality. In the case of the 
updated review of ARBs, however, we assessed the quality 
of newly added randomised clinical trials and integrated 
it into the evidence synthesis.
statistical analysis and data synthesis
We provided a narrative synthesis of the findings of the 
included reviews and if multiple reviews existed for the 
same intervention. However, in the case of ARBs, we 
updated the evidence and meta-analysed the data using 
random effects and fixed effects model with Mantel-
Haenszel methods13 and reported random effects model 
to account for heterogeneity. Meanwhile, we evaluated 
each intervention against our outcomes of interest and 
synthesised the evidence taking into account heteroge-
neity and inconsistencies between reviews. As a rule of 
thumb, I2 (I-square) values of 25%, 50% and 75% corre-
spond to low, moderate and high levels of heterogeneity, 
respectively.14
For the purpose of our overview, we categorised 
the evidence of the included interventions into three 
categories: (1) effective interventions; (2) ineffective 
interventions; and (3) uncertain evidence (conflicting 
or inconclusive evidence). We used odds ratios (OR) 
and relative effect or risk ratio (RR) as a summary statistic 
from the most recent or largest published systematic 
reviews, and confidence intervals (CIs) of 95% with a 
significance level determined at two-sided alpha less than 
5%.
Patient and public involvement
Our study did not involve direct contact with patients or 
the public.
rEsults
search result
According to our predefined eligibility criteria, our 
search strategy in electronic databases and manual 
searches resulted in 41 studies.6 15–54 Figure 1 shows 
the search strategy results. At full-text level, we 
excluded studies that did not assess our outcome of 
interest (n=129), were narrative reviews (n=4), did 
Figure 1 Flow chart for search result.
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not include HF patients (n=8), included preserved 
patients with HF (n=3), were duplicate or had no full 
text (n=2).
Characteristics of the included reviews
As shown in table 1, the population of the included 
reviews consisted of HF patients with an ejection frac-
tion ≤45% in most studies and a corresponding New 
York Heart Association classification ranging from I 
to IV. The effectiveness of each drug intervention has 
been assessed in at least one review. All reviews were 
systematic, except two reviews for antiarrhythmic 
drugs (AADs). At the time of their publication, 15 out 
of 41 reviews (37%) had corresponding authors based 
in the USA, 7 (17%) in Canada, 6 (15%) in China, 3 in 
Chile, 2 in France, 2 in the UK and the 6 remaining in 
other countries.
The disclosure and reporting of financial resources or 
funding varied from one study to another. Twenty-one 
reviews (51%) did not report the source of funding. Ten 
reviews (24%) reported financial supports that included 
governments, academic institutions and device industry. 
Six reviews declared financial resources as none or no 
external funds. Three reviews reported industry spon-
sorship for at least one author. One review53 stated that 
one author obtained funds for the review without clar-
ifying the source (online supplementary S4 table). We 
also reported findings summary of each review as stated 
by their respective authors (table 1).
risk of bias and quality of reviews
As shown in table 1, the AMSTAR scores for quality 
assessment of the included reviews widely ranged 
from 2 to 10 (out of 11). All reviews had one score 
less because of non-listing of excluded primary studies 
except Cochrane reviews,27 41 which scored 10 because 
of non-inclusion of grey literature in the search strategy 
in one review and missing information for funding 
resources of included primary studies in another, cited 
respectively (online supplementary S3 table). We did 
not assess the AMSTAR score for six studies, of which 
two46 47 were narrative reviews, two25 44 were individual 
participant or patient data meta-analyses and the other 
two26 32 were overviews of reviews.
The risk of bias of the included primary studies 
within reviews remained as judged by the original 
reviews’ authors with the exception of the newly added 
randomised trials in the update of the ARBs review that 
we assessed (GRADE) (table 2). The quality of evidence 
for BBs and antialdosterone agents obtained a high 
quality on the GRADE scale, while ACE-i, amiodarone 
and statins obtained a moderate quality. However, 
combined ARB/neprilysin inhibitors had a moderate 
and high quality for SCD and all-cause mortality 
outcomes, respectively, whereas ARBs had a low quality 
of evidence (table 2).
Up-to-dateness of included reviews
Most retrieved evidence was published within the last 
10 years (2008 and on), and seven (out of nine) drug 
interventions with updated systematic reviews were 
within the last 5 years (2012 and on). Moreover, we 
updated the pooled results for ARBs, which resulted 
in slightly different results compared with the original 
Cochrane review.27
Effectiveness of interventions
We report below the summaries of our evaluation on 
the effectiveness of the drug interventions considered 
that we have categorised into effective, ineffective and 
uncertain effectiveness (inconclusive or conflicting 
evidence).
EffECtIvE IntErvEntIOns
beta-blockers
Meta-analyses and systematic reviews of randomised 
controlled trials15–20 provided overwhelming evidence 
that BBs decrease the risk of SCD and all-cause mortality 
in patients with HFrEF. The quality of the evidence was 
rated high with a relative effect of 0.69 for SCD (OR, 
95% CI (0.62 to 0.77)) and of 0.67 for all-cause mortality 
(OR, 95% CI (0.59 to 0.76)) (table 2).
Antialdosterone agents
Published studies about mineralocorticoid receptor 
antagonists (antimineralocorticoids) or (so-called) 
antialdosterones appeared effective in SCD and all-cause 
mortality prevention.21 22 54 However, in a recent system-
atic review,21 adverse effects (hyperkalaemia, degra-
dation of renal function and gynaecomastia) were 
significantly higher in the antialdosterone-treated group 
compared with placebo. The quality of the evidence was 
rated high with relative effect for SCD (RR 0.81, 95% CI 
(0.67 to 0.98)) and all-cause mortality (RR 0.81, 95% CI 
(0.74 to 0.88)) (table 2).
Arb/neprilysin inhibitor
One meta-analysis23 estimated the effects of combined 
neprilysin renin-aldosterone system inhibition and 
reported a reduction in SCD and all-cause mortality. 
The finding was principally derived from one RCT 
(PARADIGM-HF)5 that showed about 16% reduction 
of all-cause mortality in favour of sacubitril/valsartan 
(LCZ696 previously) compared with enalapril (an 
ACE-i). This mortality reduction was attributed to a 
decline on both SCD (20%) and pump failure deaths.55 
Table 2 shows the relative effect for SCD (RR 0.81, 95% 
CI (0.69 to 0.95)) and all-cause mortality (RR 0.86, 
95% CI (0.79 to 0.94)). The moderate quality of the 
evidence for SCD outcome was due to the estimation 
from one single clinical trial and the absence of data 
from other included studies. All-cause mortality was, 
however, rated as high with a possibility of downgrading 
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in case of a detectable publication bias or unestablished 
class effect.
InEffECtIvE IntErvEntIOns
ACE inhibitors
 Although two systematic reviews,24 25 with an AMSTAR 
score of 2/11 and 3/11, respectively, reported a decline 
in total mortality and less progressive HF deaths, SCD 
events did not significantly decrease (OR 0.91, 95% CI 
(0.73 to 1.12)). The quality of the evidence was rated as 
moderate because of the unclear or high risk of bias in 
included primary studies (table 2).
Angiotensin receptor blockers
As shown in figures 2 and 3, we updated a Cochrane 
review27 by including more eligible primary studies such 
as SUPPORT trial.56 Comparing ARBs with controls 
resulted in a slightly different effect size estimation. 
Eventually, we did not combine the different control 
groups to account for heterogeneity. In stratified anal-
yses, ARBs compared with placebo remained ineffective 
for all-cause mortality (RR 0.79, 95% CI (0.55 to 1.13)). 
Similarly, ARBs, compared with ACE-i or in combina-
tion versus ACE-i alone, were not superior in all-cause 
mortality reduction (RR 0.87, 95% CI (0.56 to 1.36); RR 
0.99, 95% CI (0.90 to 1.09), respectively) (figure 2). The 
quality of the evidence is rated as low because of risk of 
bias, imprecision and inconsistency (I2≈78, p=0.010 for 
SCD outcome) (table 2). Data were limited for studies 
reporting SCD, in particular those comparing ARBs 
versus placebo, or versus ACE-i (figure 2). In addition, 
the funnel plot for all-cause mortality outcome showed 
no evidence of publication bias (figure 4). No estima-
tion of publication bias and no funnel plot was drawn 
for SCD as only five studies reported this outcome.
statins
Published systematic reviews and meta-analyses about 
statins in HF were inconsistent6 32–40 with a recent 
tendency towards inefficacy in total mortality and SCD 
prevention. The quality of the evidence was rated as 
moderate because of a likelihood of publication bias 
revealed on the most up-to-date systematic review6 
(table 2).
unClEAr EvIDEnCE Of EffECtIvEnEss
The evidence of effectiveness of the drug interventions 
reported below was considered uncertain due either to 
conflicting or inconclusive evidence.
Amiodarone and AADs
Recently published systematic reviews41 43 for 
amiodarone showed a significant reduction for SCD 
but not for all-cause mortality with less favourable net 
clinical benefits.42 Other older reviews44 45 of minor 
quality (AMSTAR of 3/11 and 5/11 cited respectively) 
reported a decline of both SCD and all-cause mortality. A
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The quality of evidence for amiodarone was rated as low 
because of the unclear or high risk of bias and poten-
tial publication bias in primary studies (table 2). No 
systematic review for AADs of other classes or drugs 
(other than amiodarone) were retrieved. Nevertheless, 
two narrative reviews46 47 reported that class I antiar-
rhythmics increased SCD and all-cause mortality. These 
narrative reviews called for caution regarding the mixed 
results of amiodarone and its adverse effects.
Omega-3 polyunsaturated fatty acids (PufAs) and fish oil 
supplementation
No systematic review was exclusively conducted in 
patients with HF for this intervention. One primary 
study,57 known as GISSI-Prevenzione HF, recruited 
patients with chronic HF and reported a lower mortality 
events in the n-3 PUFAs group compared with the 
placebo group. The authors reported an adjusted HR 
of 0.91 (95.5% CI 0.833 to 0.998), p=0.041). However, 
Table 2 Summary of findings and GRADE evaluation for sudden cardiac death (SCD) and all-cause mortality prevention 
Drug interventions for SCD and all-cause mortality prevention in heart failure patients
Outcome Intervention/comparison
Assumed 
risk with 
comparator
Corresponding risk 
with intervention
Relative effect
(95% CI)
Number of 
participants
(no. of studies)
Quality of the 
evidence
(GRADE) Comments
SCD
Beta-blockers/placebo 77 per 1000 54 per 1000
(49–60)
OR 0.69
(0.62 to 0.77)
24 779
(26 RCTs)
⊕⊕⊕⊕ High* I2=0% (p=0.57)
Antialdosterone inhibitor/
placebo; ‘usual care’
61 per 1000 49 per 1000
(41–60)
RR 0.81
(0.67 to 0.98)
8301
(5 RCTs)
⊕⊕⊕⊕ High* I2=8% (p=0.36)
ARB; neprilysin inhibitor/ACE-i 74 per 1000 60 per 1000
(51–70)
RR 0.81
(0.69 to 0.95)
8399 (1 RCsT) ⊕⊕⊕⊝ 
Moderate†
ACE-i/placebo 59 per 1000 54 per 1000
(43–65)
OR 0.91
(0.73 to 1.11)
6988 (30 RCTs) ⊕⊕⊕⊝ 
Moderate‡
I2=0% (p=0.94)
ARB (or ARB+ACE i)/Placebo; 
ACE-i
See comment See comment Not estimable 13 884 (5 RCTs) ⊕⊕⊝⊝
Low‡§
I2=78% (p=0.010). 
Overall, we did 
not pool the 
studies because of 
heterogeneity
Statins/placebo; ‘usual care’ 108 per 1000 100 per 1000
(76–131) (99 per 
1000
(72–131))
RR 0.92
(0.7 to 1.21)
(OR 0.90
(0.64 to 1.24))
10 077 (8 RCTs) ⊕⊕⊕⊝ 
Moderate¶
I2=42.6% (p=0.094)
Amiodarone/placebo; ‘usual 
care’
118 per 1000 93 per 1000
(79–110)
RR 0.79
(0.67 to 0.93)
5006 (11 RCTs) ⊕⊕⊝⊝
Low¶‡
Omega 3 fatty acids/placebo; 
‘usual care’
93 per 1000 88 per 1000
(77–102)
RR 0.94
(0.82 to 1.09)
6975 (1 RCT) ⊕⊕⊕⊝ 
Moderate†
All-cause mortality
Beta-blockers/placebo 178 per 1000 127 per 1000
(113–141)
OR 0.67
(0.59 to 0.76)
24 779
(26 RCTs)
⊕⊕⊕⊕ High* I2=40 % (p = 0.02) 
Antialdosterone inhibitor /
placebo; ‘ usual care’ 
200 per 1000 162 per 1000
(148–176)
RR 0.81
(0.74 to 0.88)
9019 (10 RCTs) ⊕⊕⊕⊕ High I2= 0% (p= 0.56) 
ARB; neprilysin inhibitor /ACE -i 183 per 1000 158 per 1000
(145–172)
RR 0.86
(0.79 to 0.94)
14 742 (3 RCTs) ⊕⊕⊕⊕ High I2= 0% (p = 0.42) 
ACE-i/placebo 219 per 1000 178 per 1000
(158–198)
OR 0.77
(0.67 to 0.88)
7105 (32 RCTs) ⊕⊕⊕⊝ 
Moderate
I2=0% (p= 0.95) 
ARB (or ARB+ACE -i)/ placebo; 
ACE-i.
183 per 1000 177 per 1000 
(161–197)
RR 0.97 (0.88 to 
1.08)
19 510 (27 RCTs) ⊕⊕⊝⊝
Low‡**
I2= 24% (p = 0.14) 
Statins/placebo; ‘usual care’ 273 per 1000 240 per 1000 (205–
278) (233 per 1000
(199–273))
RR 0.88 (0.75 to 
1.02) OR 0.81
(0.66 to 1)
11 024 (13 RCTs) ⊕⊕⊕⊝ 
Moderate¶
I2= 37.7% (p =0.083) 
Amiodarone/placebo; ‘usual 
care’ 
264 per 1000 237 per 1000
(211–266)
RR 0.90
(0.80 to 1.01)
5006 (11 RCTs) ⊕⊕⊝⊝
Low¶‡
Omega 3 fatty acids/ placebo; 
‘usual care’ 
291 per 1000 274 per 1000
(253–294)
RR 0.94
(0.87 to 1.01)
6975 (1 RCT) ⊕⊕⊕⊝ 
Moderate
*Although graded high, this might be downgraded into moderate if we strictly consider the risk of bias of primary studies other than an overall estimation.
†Estimation comes from one single clinical trial. No data obtained from other relevant studies for this outcome.
‡The studies reported to generally have a moderate to high risk of bias due to allocation concealment and blinding reporting.
¶Likelihood of publication bias presence with an asymmetric funnel plot.
§Inconsistent results ranged from no effect to insignificant increase of events (I2≈  71%).
**Most studies have small sample and wide CIs including no effect with appreciable harm or benefit.
ACE-i, ACE inhibitors; ARBs, angiotensin receptor blockers; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; I2, between-study 
variance due to heterogeneity; RR, risk ratio.
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relative risk in our analysis remained statistically insig-
nificant (RR 0.94, 95% CI (0.87 to 1.01), p=0.10) and 
(RR 0.94, 95% CI (0.81 to 1.09), p=0.42) for all-cause 
mortality and SCD, respectively. Our assessment of the 
quality of the evidence involving GISSI-Prevenzione 
HF was moderate because of an absence of data of 
any other relevant studies (table 2). In addition, some 
recent systematic reviews48–51 included patients regard-
less of their cardiovascular disease and concluded of 
no clear effect, insufficient evidence or no reduction 
on SCD and all-cause mortality outcomes. Meanwhile, 
some older studies52 53 reported that omega-3 fatty acids 
and fish oil supplements (other than α-linolenic acid53) 
reduced SCD and all-cause mortality.
DIsCussIOn
Our assessment of the effectiveness of drug interven-
tions to prevent SCD in patients with HFrEF indicated 
that BBs, antialdosterone agents, as well as combined 
ARB/neprilysin inhibitors were effective.
Previously reported meta-analyses and systematic 
reviews of RCTs15–20 indicated that BBs are effective in 
the prevention of SCD and all-cause mortality in HFrEF. 
Figure 2 Efficacy of angiotensin receptor blockers (ARBs) compared with placebo, angiotensin-converting enzyme inhibitor 
(ACE-i) or combined in heart failure with reduced ejection fraction (HFrEF) for the prevention of all-cause mortality.
 o
n
 13 D
ecem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021108 on 28 July 2018. Downloaded from 
11Al-Gobari M, et al. BMJ Open 2018;8:e021108. doi:10.1136/bmjopen-2017-021108
Open access
However, although they were increasingly used as a 
usual ‘routine’ care in the compared arms of the more 
recently published clinical trials,58 BBs stayed underused 
for long time and may still be.59 Mineralocorticoid 
receptor antagonists or antialdosterone drugs have 
been reported effective in HFrEF by reducing SCD and 
all-cause mortality.21 22 54 60 Our summary of the findings 
and the consistency of the results support this claim 
Figure 3 Efficacy of angiotensin receptor blockers (ARBs) compared with placebo, angiotensin-converting enzyme inhibitor 
(ACE-i) or combined in heart failure with reduced ejection fraction (HFrEF) for the prevention of sudden cardiac death (SCD).
Figure 4 Funnel plot of SE (log OR) by OR to evaluate publication bias for the efficacy of angiotensin receptor blockers (ARBs) 
compared with control in heart failure and reduced ejection fraction (HFrEF) for the prevention of all-cause mortality.
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with a high quality of evidence. Only one retrieved 
meta-analysis23 supported the effectiveness of combined 
ARB/neprilysin inhibitor. The authors acknowledged 
the limitation of their meta-analysis, which was not 
based on a systematic review, but merely pooling three 
well-known trials published in high impact journals (ie, 
IMPRESS,61 OVERTURE62 and PARADIGM-HF).5 The 
quality of the evidence is, however, moderate for SCD 
and high for all-cause mortality, although our inability 
to assess any presence of a class effect or a potential 
publication bias.
We found that ACE-i showed a total mortality reduc-
tion in clinical trials and systematic reviews of patients 
with HF.24 25 However, our overview showed that ACE-i, 
surprisingly, did not significantly decrease SCD with a 
moderate quality of evidence.
In addition, we found that neither ARBs nor 
statins reduced SCD and/or all-cause mortality. Our 
findings for ARBs were in agreement with Jong and 
colleagues,31 Shibata et al28 and Dimopoulos et al,30 
but in contradiction to Lee et al29 and Rain and Rada’s 
conclusions.26 Our up-to-date meta-analysis for ARBs 
included only five primary studies, but large-scale 
trials, that reported SCD events. Eventually, we did 
not pool all the different comparators together but 
separately estimated the effect size for each group to 
account for the heterogeneity. Moreover, the addi-
tion of current trials such as SUPPORT56 improved 
the statistical power of detecting an effect if existed 
and the summary statistic remained statistically insig-
nificant (figure 2). Of note, Jong and colleagues31 
attributed this inefficacy of ARBs in HF to the back-
ground treatment with ACE-i.
Within the current evidence, ARBs should not be seen 
as interchangeable with ACE-i, which also showed a 
neutral effect on SCD, without a proper reason. There-
fore, in a high-risk SCD patient, another therapeutic 
strategy should be sought, and an ARB/neprilysin 
inhibitor might be an alternative in patients similar to 
those of the PARADIGM-HF trial.5
The addition of statins to the therapy regimen of 
patients with HF had no survival benefits. Actually, a 
recent systematic review and meta-analysis indicated 
that statins did not reduce SCD nor all-cause mortality.6 
Our current study reached the same conclusion with 
similar quality of evidence.
Our overview showed unclear evidence of effective-
ness of omega-3 PUFAs, fish oil supplementation and 
AADs. The latter intervention had an evidence origi-
nated from only narrative reviews, as we did not identify 
any systematic reviews. Also, only one n-3 PUFA clinical 
trial57 was conducted in patients with HF and reported 
a statistically significant mortality reduction; this result 
was not supported by other trials and recent systematic 
reviews,48–51 a finding that justified our conclusion of 
unclear evidence. Moreover, no other data or system-
atic reviews conducted in HF were retrieved by our elec-
tronic and manual searches.
AADs are classified into four categories46: sodium 
channel blocking drugs (class I), BBs (class II), potas-
sium channel blockers (class III) and calcium channel 
blockers (class IV). We found inconclusive evidence 
of effectiveness of all categories, with the exception of 
BBs. The evidence of effectiveness of class I, III and IV is 
inconclusive, neutral or even detrimental to patients as 
for class I AADs.46 47 Amiodarones, which present class I, 
II, III and IV effects, reported mixed results with poten-
tial SCD prevention with adverse effects43 and poten-
tially, but rare,63 life-threatening proarrhythmias.46
Our overview has some limitations. First, we limited 
the scope of our study to drug treatment, thus excluding 
devices like ICDs. We believe that non-drug devices should 
be tackled in future research. European Society of Cardi-
ology (ESC) Guideline (2016)64 and others (eg, www. 
uptodate. com) recommend the use of ICDs for only ≤35% 
of patients with HF and only after optimisation of drug 
therapy. In fact, SCDs occur in both reduced and preserved 
HF. Our overview might help to optimise therapy as a first 
step before introducing ICDs, which applies to a limited HF 
subpopulation, regardless of costs. Second, we may have 
failed to include other drug interventions used in HFrEF. 
Such drug candidates include digoxin, If-channel blockers 
(ivabradine), hydralazine/isosorbide dinitrate, nitroglyc-
erin and phosphodiesterase 3 or 5 inhibitors. However, 
our overview included most commonly prescribed and 
evidence-based pharmacological therapy in HF as prespec-
ified in our published protocol.11 Third, we did not use 
specific drug names in our literature search strategy, in 
order to avoid omitting a therapy that evaluated SCD 
and/or all-cause mortality prevention in patients with HF. 
Fourth, we based our analyses on existing systematic reviews 
and meta-analyses, and we updated only one meta-analysis. 
Consequently, we were unable to update the evidence for 
ACE-i. Furthermore, as indicated by the AMSTAR score, the 
methodological quality of some of the existing reviews was 
suboptimal. Fifth, we did not assess the safety of the evalu-
ated drug interventions, nor the contraindications for their 
prescription, drug–drug interactions, as well as treatment 
adherence. Indeed, we considered that these important 
aspects were out of the scope of our analysis. Sixth, we were 
unable to do a sensitivity analysis, initially suggested in our 
protocol, for ischaemic versus non-ischaemic HF due to 
limited data availability. Finally, a potential source of bias 
relates to authors of this overview being the authors of three 
of the included reviews.16 21 65 However, the adopted meth-
odology is in line with systematic reviews guidelines and 
ensured a double check of data and methodological eval-
uation by at least two reviewers and a published protocol.11
It is noteworthy that high-quality evidence does not 
necessarily imply strong recommendations, and strong 
recommendations can arise from low-quality evidence.66 
Therefore, when one intervention is graded high, it is not 
our intention to say that it is highly recommended, as we 
did not assess the level of recommendation in our study. In 
fact, a level of recommendation depends on the strength of 
evidence and (among others) on values and preferences of 
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patients, net benefits and cost-effectiveness of a particular 
intervention.
Implications for practice
Our study summarises and synthesises the effectiveness of 
most evidence-based drug interventions in patients with 
HFrEF for SCD prevention. It classified drug interven-
tions according to the current evidence of their effective-
ness. This categorisation could help health professionals 
and patients making evidence-based decisions based on 
updated knowledge, particularly whenever a high-risk SCD 
patient is identified. Currently, there is no an established 
strategy to deal with patients at high risk of SCD. In such 
patients, a particular attention should be considered, and a 
careful selection of available therapeutic options is needed. 
Furthermore, there might be a shift towards an alternative 
therapeutic strategy based on SCD prevention-effective 
drugs in light of our findings.
COnClusIOn
Our overview indicates that only three drug interventions 
(BBs, antialdosterones, combined ARB/neprilysin inhibi-
tors) significantly reduce SCD and improve overall survival 
among individuals with HF and reduced ejection fraction. 
However, there is no evidence of effectiveness of ARBs to 
reduce neither all-cause mortality nor SCD (with a low 
quality of evidence), and ACE-i do not significantly reduce 
SCD events. When the goal of drug therapy is to reduce 
SCD, especially in high-risk patients, our synthesis supports 
the use of the most effective regimen.
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